MLICM
KURA icon

Metropolitan Life Insurance Company (MetLife)’s Kura Oncology KURA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,719
Closed -$79.3K – 1145
2024
Q1 		$79.3K Sell
3,719
-408
-10% -$7.93K ﹤0.01% 1177
2023
Q4 		$59.3K Hold
4,127
– – ﹤0.01% 1352
2023
Q3 		$37.6K Buy
4,127
+606
+17% +$6.15K ﹤0.01% 1564
2023
Q2 		$37.3K Hold
3,521
– – ﹤0.01% 1602
2023
Q1 		$43.1K Sell
3,521
-629
-15% -$7.85K ﹤0.01% 1475
2022
Q4 		$51.5K Hold
4,150
– – ﹤0.01% 1454
2022
Q3 		$56.7K Hold
4,150
– – ﹤0.01% 1376
2022
Q2 		$76.1K Hold
4,150
– – ﹤0.01% 1228
2022
Q1 		$66.7K Sell
4,150
-11,444
-73% -$165K ﹤0.01% 1429
2021
Q4 		$218K Sell
15,594
-3,529
-18% -$57.2K ﹤0.01% 1972
2021
Q3 		$358K Hold
19,123
– – 0.01% 1661
2021
Q2 		$399K Buy
19,123
+903
+5% +$22.4K 0.01% 1672
2021
Q1 		$515K Sell
18,220
-598
-3% -$18.9K 0.01% 1396
2020
Q4 		$615K Buy
18,818
+2,171
+13% +$76.3K 0.01% 1231
2020
Q3 		$510K Hold
16,647
– – 0.01% 1206
2020
Q2 		$271K Buy
16,647
+6,447
+63% +$93K ﹤0.01% 1611
2020
Q1 		$101K Buy
10,200
+626
+7% +$7.17K ﹤0.01% 2020
2019
Q4 		$132K Sell
9,574
-1,010
-10% -$15K ﹤0.01% 2170
2019
Q3 		$161K Buy
10,584
+946
+10% +$16.8K ﹤0.01% 2028
2019
Q2 		$190K Hold
9,638
– – ﹤0.01% 1922
2019
Q1 		$160K Hold
9,638
– – ﹤0.01% 2051
2018
Q4 		$135K Hold
9,638
– – ﹤0.01% 2079
2018
Q3 		$169K Buy
9,638
+2,004
+26% +$38.4K ﹤0.01% 2127
2018
Q2 		$139K Buy
7,634
+490
+7% +$8.3K ﹤0.01% 2153
2018
Q1 		$134K Hold
7,144
– – ﹤0.01% 2135
2017
Q4 		$109K Sell
7,144
-7,424
-51% -$109K ﹤0.01% 2258
2017
Q3 		$218K Buy
+14,568
New +$137K ﹤0.01% 2224

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KURA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kura Oncology (KURA) in Q2 2024, closing a stake of 3,719 shares — an estimated $79.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KURA in Q3 2017 and held it in 27 quarters. The position peaked at $615K in Q4 2020. 174 funds tracked by Wall St. Rank hold KURA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Kura Oncology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,719 Kura Oncology shares in Q2 2024, an estimated $79.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Kura Oncology in Q3 2017 and held it in 27 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Kura Oncology position peaked at $615K in Q4 2020.
  • 174 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.